References
- Glioblastoma. [cited 2024 Apr 3]. Available from: https://www.gliocure.com/en/patients/glioblastoma/.
- Glioblastoma. Overview - Mayo Clinic. [cited 2024 Apr 3]. Available from: https://www.mayoclinic.org/diseases-conditions/glioblastoma/cdc-20350148.
- Zhang Y, Lai BS, Juhas M. Recent advances in aptamer discovery and applications. Molecules. 2019;24(5):941. https://www.mdpi.com/1420-3049/24/5/941/htm doi: 10.3390/molecules24050941.
- Onaş AM, Dascălu C, Raicopol MD, et al. Critical design factors for electrochemical aptasensors based on target-induced conformational changes: the case of small-molecule targets. Biosensors. 2022;12(10):816. https://www.mdpi.com/2079-6374/12/10/816/htm doi: 10.3390/bios12100816.
- Fu Z, Xiang J. Aptamers, the nucleic acid antibodies, in cancer therapy. Int J Mol Sci. 2020;21(8):2793. https://www.mdpi.com/1422-0067/21/8/2793/htm doi: 10.3390/ijms21082793.
- Al Hoque A, Dutta D, Paul B, et al. ΔPSap4#5 surface-functionalized abiraterone-loaded nanoparticle successfully inhibits carcinogen-induced prostate cancer in mice: a mechanistic investigation. Cancer Nano. 2023;14(1):73. doi: 10.1186/s12645-023-00223-5.
- Lao YH, Phua KKL, Leong KW. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS Nano. 2015;9(3):2235–2254. https://pubs.acs.org/doi/abs/10.1021/nn507494p doi: 10.1021/nn507494p.
- Hays EM, Duan W, Shigdar S. Aptamers and glioblastoma: their potential use for imaging and therapeutic applications. Int J Mol Sci. 2017;18(12):2576. https://www.mdpi.com/1422-0067/18/12/2576/htm doi: 10.3390/ijms18122576.
- Cesarini V, Scopa C, Silvestris DA, et al. Aptamer-based in vivo therapeutic targeting of glioblastoma. Molecules. 2020;25(18):4267. doi: 10.3390/molecules25184267.
- Soldevilla MM, de Caso DMC, Menon AP, et al. Aptamer-iRNAs as therapeutics for cancer treatment. Pharmaceuticals. 2018;11(4):108. doi: 10.3390/ph11040108.
- Macdonald J, Henri J, Goodman L, et al. Development of a bifunctional aptamer targeting the transferrin receptor and epithelial cell adhesion molecule (EpCAM) for the treatment of brain cancer metastases. ACS Chem Neurosci. 2017;8(4):777–784. https://pubs.acs.org/doi/abs/10.1021/acschemneuro.6b00369 doi: 10.1021/acschemneuro.6b00369.
- Affinito A, Quintavalle C, Esposito CL, et al. The discovery of RNA-aptamers that selectively bind and inhibit glioblastoma stem cells by targeting EphA2. Mol Ther Nucleic Acids. 2019;18:v802. doi: 10.1093/annonc/mdz269.016.
- Novopashina DS, Dymova MA, Davydova AS, et al. Aptamers for addressed boron delivery in BNCT: effect of boron cluster attachment site on functional activity. Int J Mol Sci. 2023;24(1):306. https://www.mdpi.com/1422-0067/24/1/306/htm doi: 10.3390/ijms24010306.
- Cruz Da Silva E, Foppolo S, Lhermitte B, et al. Bioimaging nucleic-acid aptamers with different specificities in human glioblastoma tissues highlights tumoral heterogeneity. Pharmaceutics. 2022;14(10):1980. https://www.mdpi.com/1999-4923/14/10/1980/htm doi: 10.3390/pharmaceutics14101980.
- Fechter P, Cruz Da Silva E, Mercier M-C, et al. RNA aptamers targeting integrin α5β1 as probes for cyto- and histofluorescence in glioblastoma. Mol Ther Nucleic Acids. 2019;17:63–77. http://www.cell.com/article/S2162253119301362/fulltext doi: 10.1016/j.omtn.2019.05.006.
- Bayrac AT, Akca OE, Eyidogan FI, et al. Target-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptamer. J Biosci. 2018;43(1):97–104. doi: 10.1007/s12038-018-9733-x.
- Kim B, Yang J, Hwang M, et al. Aptamer-modified magnetic nanoprobe for molecular MR imaging of VEGFR2 on angiogenic vasculature. Nanoscale Res Lett. 2013;8(1):399. doi: 10.1186/1556-276X-8-399.
- Esposito CL, Nuzzo S, Catuogno S, et al. STAT3 gene silencing by aptamer-siRNA chimera as selective therapeutic for glioblastoma. Mol Ther Nucleic Acids. 2018;10:398–411. doi: 10.1016/j.omtn.2017.12.021.
- Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249(4968):505–510. doi: 10.1126/science.2200121.
- Mahmoudian F, Ahmari A, Shabani S, et al. Aptamers as an approach to targeted cancer therapy. Cancer Cell Int. 2024;24(1):108. doi: 10.1186/s12935-024-03295-4.
- Wu Q, Wang Y, Wang H, et al. DNA aptamers from whole-cell SELEX as new diagnostic agents against glioblastoma multiforme cells. Analyst. 2018;143(10):2267–2275. doi: 10.1039/c8an00271a.
- Prante M, Schüling T, Roth B, et al. Characterization of an aptamer directed against 25-hydroxyvitamin D for the development of a competitive aptamer-based assay. Biosensors. 2019;9(4):134. doi: 10.3390/bios9040134.
- Oliveira MT, editor. Single stranded DNA binding proteins. Vol. 2281. New York (NY): Springer US; 2021.
- Mann AP, Scodeller P, Hussain S, et al. Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer’s disease [published correction appears in Nat Commun. 2018 Mar 9;9(1):1070]. Nat Commun. 2017;8(1):1403. doi: 10.1038/s41467-017-01096-0.
- Gao S, Hu W, Zheng X, et al. Functionalized aptamer with an antiparallel G-quadruplex: structural remodeling, recognition mechanism, and diagnostic applications targeting CTGF. Biosens Bioelectron. 2019;142:111475. doi: 10.1016/j.bios.2019.111475.
- Yu B, Pettitt BM, Iwahara J. Dynamics of ionic interactions at protein–nucleic acid interfaces. Acc Chem Res. 2020;53(9):1802–1810. doi: 10.1021/acs.accounts.0c00212.
- Bandyopadhyay AK, Ul Islam RN, Hazra N. Salt-bridges in the microenvironment of stable protein structures. Bioinformation. 2020;16(11):900–909. doi: 10.6026/97320630016900.
- Lik FK, Guo JT. Insights into protein-DNA interactions from hydrogen bond energy-based comparative protein-ligand analyses. Proteins. 2022;90(6):1303–1314. doi: 10.1002/prot.26313.
- Zhang X, Yang G, Zhao Y, et al. Selection and identification of an ssDNA aptamer for fibroblast activation protein. Molecules. 2023;28(4):1682. doi: 10.3390/molecules28041682.
- Xiao F, Chen Z, Wei Z, et al. Hydrophobic Interaction: a promising driving force for the biomedical applications of nucleic acids. Adv Sci. 2020;7(16):2001048. doi: 10.1002/advs.202001048.
- Zhong L, Li Y, Xiong L, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201. doi: 10.1038/s41392-021-00572-w.
- Ji C, Wei J, Zhang L, et al. Aptamer-protein interactions: from regulation to biomolecular detection. Chem Rev. 2023;123(22):12471–12506. doi: 10.1021/acs.chemrev.3c00377.
- Gelinas AD, Davies DR, Janjic N. Embracing proteins: structural themes in aptamer-protein complexes. Curr Opin Struct Biol. 2016;36:122–132. doi: 10.1016/j.sbi.2016.01.009.
- Odeh F, Nsairat H, Alshaer W, et al. Aptamers chemistry: chemical modifications and conjugation strategies. Molecules. 2019;25(1):3. doi: 10.3390/molecules25010003.
- Zhang N, Chen Z, Liu D, et al. Structural biology for the molecular insight between aptamers and target proteins. Int J Mol Sci. 2021;22(8):4093. doi: 10.3390/ijms22084093.
- Ohashi S, Hashiya F, Abe H. Variety of nucleotide polymerase mutants aiming to synthesize modified RNA. Chembiochem. 2021;22(14):2398–2406. doi: 10.1002/cbic.202100004.
- Adachi T, Nakamura Y. Aptamers: a review of their chemical properties and modifications for therapeutic application. Molecules. 2019;24(23):4229. doi: 10.3390/molecules24234229.
- Wu L, Wang Y, Xu X, et al. Aptamer-based detection of circulating targets for precision medicine. Chem Rev. 2021;121(19):12035–12105. doi: 10.1021/acs.chemrev.0c01140.
- Zhou G, Wilson G, Hebbard L, et al. Aptamers: a promising chemical antibody for cancer therapy. Oncotarget. 2016;7(12):13446–13463. doi: 10.18632/oncotarget.7178.
- Nomura Y, Sugiyama S, Sakamoto T, et al. Conformational plasticity of RNA for target recognition as revealed by the 2.15 A crystal structure of a human IgG-aptamer complex. Nucleic Acids Res. 2010;38(21):7822–7829. doi: 10.1093/nar/gkq615.
- Davlieva M, Donarski J, Wang J, et al. Structure analysis of free and bound states of an RNA aptamer against ribosomal protein S8 from Bacillus anthracis. Nucleic Acids Res. 2014;42(16):10795–10808. doi: 10.1093/nar/gku743.
- Long SB, Long MB, White RR, et al. Crystal structure of an RNA aptamer bound to thrombin. RNA. 2008;14(12):2504–2512. doi: 10.1261/rna.1239308.
- Emami N, Ferdousi R. AptaNet as a deep learning approach for aptamer–protein interaction prediction. Sci Rep. 2021;11(1):6074. doi: 10.1038/s41598-021-85629-0.
- Tan KX, Pan S, Jeevanandam J, et al. Cardiovascular therapies utilizing targeted delivery of nanomedicines and aptamers. Int J Pharm. 2019;558:413–425. doi: 10.1016/j.ijpharm.2019.01.023.
- Chen Y, Jiang B, Hu Y, et al. Aptamer functionalized magnetic graphene oxide nanocomposites for highly selective capture of histones. Electrophoresis. 2019;40(16–17):2135–2141. doi: 10.1002/elps.201900061.
- Godonoga M, Lin T-Y, Oshima A, et al. A DNA aptamer recognising a malaria protein biomarker can function as part of a DNA origami assembly. Sci Rep. 2016;6(1):21266. doi: 10.1038/srep21266.
- Ilgu M, Nilsen-Hamilton M. Aptamers in analytics. Analyst. 2016;141(5):1551–1568. doi: 10.1039/c5an01824b.
- Elskens JP, Elskens JM, Madder A. Chemical modification of aptamers for increased binding affinity in diagnostic applications: current status and future prospects. Int J Mol Sci. 2020;21(12):4522. doi: 10.3390/ijms21124522.
- Ray P, White RR. Aptamers for targeted drug delivery. Pharmaceuticals. 2010;3(6):1761–1778. doi: 10.3390/ph3061761.
- Mao Y, Gu J, Chang D, et al. Evolution of a highly functional circular DNA aptamer in serum. Nucleic Acids Res. 2020;48(19):10680–10690. doi: 10.1093/nar/gkaa800.
- Veedu RN, Wengel J. Locked nucleic acid nucleoside triphosphates and polymerases: on the way towards evolution of LNA aptamers. Mol Biosyst. 2009;5(8):787–792. doi: 10.1039/b905513b.
- Ni S, Zhuo Z, Pan Y, et al. Recent progress in aptamer discoveries and modifications for therapeutic applications. ACS Appl Mater Interfaces. 2021;13(8):9500–9519. doi: 10.1021/acsami.0c05750.
- Li K, Deng J, Jin H, et al. Chemical modification improves the stability of the DNA aptamer GBI-10 and its affinity towards tenascin-C. Org Biomol Chem. 2017;15(5):1174–1182. doi: 10.1039/C6OB02577C.
- Shum KT, Tanner JA. Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase. Chembiochem. 2008;9(18):3037–3045. doi: 10.1002/cbic.200800491.
- Dougan H, Lyster DM, Vo CV, et al. Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl Med Biol. 2000;27(3):289–297. doi: 10.1016/s0969-8051(99)00103-1.
- Krüger A, de Jesus Santos AP, de Sá V, et al. Aptamer applications in emerging viral diseases. Pharmaceuticals. 2021;14(7):622. doi: 10.3390/ph14070622.
- Byun J. Recent progress and opportunities for nucleic acid aptamers. Life. 2021;11(3):193. doi: 10.3390/life11030193.
- Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol. 2010;50(1):237–257. doi: 10.1146/annurev.pharmtox.010909.105547.
- Gilboa E, Berezhnoy A, Schrand B. Reducing toxicity of immune therapy using aptamer-targeted drug delivery. Cancer Immunol Res. 2015;3(11):1195–1200. doi: 10.1158/2326-6066.CIR-15-0194.
- Nimjee SM, White RR, Becker RC, et al. Aptamers as therapeutics. Annu Rev Pharmacol Toxicol. 2017;57(1):61–79. doi: 10.1146/annurev-pharmtox-010716-104558.
- Hirota M, Murakami I, Ishikawa Y, et al. Chemically modified interleukin-6 aptamer inhibits development of collagen-induced arthritis in cynomolgus monkeys. Nucleic Acid Ther. 2016;26(1):10–19. doi: 10.1089/nat.2015.0567.
- Menne J, Eulberg D, Beyer D, et al. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant. 2017;32(2):307–315. doi: 10.1093/ndt/gfv459.
- Boyce M, Warrington S, Cortezi B, et al. Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects. Br J Pharmacol. 2016;173(10):1580–1588. doi: 10.1111/bph.13433.
- Jianghong L, Tingting M, Yingping Z, et al. Aptamer and peptide-modified lipid-based drug delivery systems in application of combined sequential therapy of hepatocellular carcinoma. ACS Biomater Sci Eng. 2021;7(6):2558–2568. doi: 10.1021/acsbiomaterials.1c00357.
- Mercier MC, Dontenwill M, Choulier L. Selection of nucleic acid aptamers targeting tumor cell-surface protein biomarkers. Cancers. 2017;9(6):69. doi: 10.3390/cancers9060069.
- Li F, Lu J, Liu J, et al. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nat Commun. 2017;8(1):1390. doi: 10.1038/s41467-017-01565-6.
- Kaur H, Bruno JG, Kumar A, et al. Aptamers in the therapeutics and diagnostics pipelines. Theranostics. 2018;8(15):4016–4032. doi: 10.7150/thno.25958.
- Yang S, Li H, Xu L, et al. Oligonucleotide aptamer-mediated precision therapy of hematological malignancies. Mol Ther Nucleic Acids. 2018;13:164–175. doi: 10.1016/j.omtn.2018.08.023.
- Lee CH, Lee SH, Kim JH, et al. Pharmacokinetics of a cholesterol-conjugated aptamer against the hepatitis C Virus (HCV) NS5B protein. Mol Ther Nucleic Acids. 2015;4(10):e254. doi: 10.1038/mtna.2015.30.
- Amero P, Lokesh GLR, Chaudhari RR, et al. Conversion of RNA aptamer into modified DNA aptamers provides for prolonged stability and enhanced antitumor activity. J Am Chem Soc. 2021;143(20):7655–7670. doi: 10.1021/jacs.9b10460.
- Chen Z, Luo H, Gubu A, et al. Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding. Front Cell Dev Biol. 2023;11:1–12. doi: 10.3389/fcell.2023.1091809.
- Dubois C, Campbell MA, Edwards SL, et al. Stepping towards highly flexible aptamers: enzymatic recognition studies of unlocked nucleic acid nucleotides. Chem Commun (Camb). 2012;48(44):5503–5505. doi: 10.1039/C2CC31316B.
- Boomer RM, Lewis SD, Healy JM, et al. Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. 2005;15(3):183–95. doi: 10.1089/oli.2005.15.183.
- Lambert JM, Berkenblit A. Antibody–drug conjugates for cancer treatment. Annu Rev Med. 2018;69(1):191–207. doi: 10.1146/annurev-med-061516-121357.
- Khongorzul P, Ling CJ, Khan FU, et al. Antibody–drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3–19. doi: 10.1158/1541-7786.MCR-19-0582.
- FDA granted accelerated approval to belantamabmafodotin-blmf for multiple myeloma. [cited 2024 Apr 4]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma.
- Cancer. FDA grants accelerated approval to sacituzumabgovitecan-hziy for metastatic triple negative breast [cited 2024 Apr 3]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sacituzumab-govitecan-hziy-metastatic-triple-negative-breast-cancer.
- Cancer. FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast. [cited 2024 Apr 4]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2.
- FDA approves new type of therapy to treat advanced urothelial cancer | FDA [Internet]. [cited 2024 Apr 3]. https://www.fda.gov/news-events/press-announcements/fda-approves-new-type-therapy-treat-advanced-urothelial-cancer.
- FDA approves polatuzumabvedotin-piiq for diffuse large B-cell lymphoma | FDA [Internet]. [cited 2024 Apr 3]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma.
- Kovacevic KD, Gilbert JC, Jilma B. Pharmacokinetics, pharmacodynamics and safety of aptamers. Adv Drug Deliv Rev. 2018;134:36–50. doi: 10.1016/j.addr.2018.10.008.
- Xiong H, Yan J, Cai S, et al. Aptamer-pyropheophorbide a conjugates with tumor spheroid targeting and penetration abilities for photodynamic therapy. Mol Pharm. 2020;17(8):2882–2890. doi: 10.1021/acs.molpharmaceut.0c00335.
- Kuai H, Zhao Z, Mo L, et al. Circular bivalent aptamers enable in vivo stability and recognition. J Am Chem Soc. 2017;139(27):9128–9131. doi: 10.1021/jacs.7b04547.
- Kim DH, Seo JM, Shin KJ, et al. Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy. Biomater Res. 2021;25(1):42. doi: 10.1186/s40824-021-00244-4.
- Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576–588. doi: 10.1002/psp4.12224.
- Zhang Y, Zhang T, Liu M, et al. Aptamer-targeted magnetic resonance imaging contrast agents and their applications. J Nanosci Nanotechnol. 2018;18(6):3759–3774. doi: 10.1166/jnn.2018.15226.
- Zhu H, Zhang L, Liu Y, et al. Aptamer-PEG-modified Fe3O4@Mn as a novel T1- and T2- dual-model MRI contrast agent targeting hypoxia-induced cancer stem cells. Sci Rep. 2016;6(1):39245. doi: 10.1038/srep39245.
- Xiang D, Zheng C, Zhou SF, et al. Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors. Theranostics. 2015;5(10):1083–1097. doi: 10.7150/thno.11711.
- Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–287. doi: 10.1038/nrc3236.
- Kumari L, Ehsan I, Mondal A, et al. Cetuximab-conjugated PLGA nanoparticles as a prospective targeting therapeutics for non-small cell lung cancer. J Drug Target. 2023;31(5):521–536. doi: 10.1080/1061186X.2023.2199350.
- Liu S, Kurzrock R. Toxicity of targeted therapy: implications for response and impact of genetic polymorphisms. Cancer Treat Rev. 2014;40(7):883–891. doi: 10.1016/j.ctrv.2014.05.003.
- Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803–812. doi: 10.1038/nrc1970.
- Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies. J Am Acad Dermatol. 2015;72(2):203–218. doi: 10.1016/j.jaad.2014.07.032.
- Powell Gray B, Kelly L, Ahrens DP, et al. Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A. 2018;115(18):4761–4766. doi: 10.1073/pnas.1717705115.
- Yoon S, Huang K-W, Reebye V, et al. Aptamer-drug conjugates of active metabolites of nucleoside analogs and cytotoxic agents inhibit pancreatic tumor cell growth. Mol Ther Nucleic Acids. 2017;6:80–88. doi: 10.1016/j.omtn.2016.11.008.
- Kratschmer C, Levy M. Targeted delivery of auristatin-modified toxins to pancreatic cancer using aptamers. Mol Ther Nucleic Acids. 2018;10:227–236. doi: 10.1016/j.omtn.2017.11.013.
- Powell Gray B, Song X, Hsu DS, et al. An aptamer for broad cancer targeting and therapy. Cancers. 2020;12(11):3217. doi: 10.3390/cancers12113217.
- Zuchero YJ, Chen X, Bien-Ly N, et al. Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies. Neuron. 2016;89(1):70–82. doi: 10.1016/j.neuron.2015.11.024.
- Hung SY, Fu WM. Drug candidates in clinical trials for Alzheimer’s disease. J Biomed Sci. 2017;24(1):47. doi: 10.1186/s12929-017-0355-7.
- Bukari B, Samarasinghe RM, Noibanchong J, et al. Non-invasive delivery of therapeutics into the brain: the potential of aptamers for targeted delivery. Biomedicines. 2020;8(5):120. doi: 10.3390/biomedicines8050120.
- Shigdar S, Schrand B, Giangrande PH, et al. Aptamers: cutting edge of cancer therapies. Mol Ther. 2021;29(8):2396–2411. doi: 10.1016/j.ymthe.2021.06.010.
- Sola M, Menon AP, Moreno B, et al. Aptamers against live targets: is in vivo SELEX finally coming to the edge? Mol Ther Nucleic Acids. 2020;21:192–204. doi: 10.1016/j.omtn.2020.05.025.
- Cheng C, Chen YH, Lennox KA, et al. In vivo SELEX for identification of brain-penetrating aptamers. Mol Ther Nucleic Acids. 2013;2(1):e67. doi: 10.1038/mtna.2012.59.
- Zhong Y, Zhao J, Li J, et al. Advances of aptamers screened by Cell-SELEX in selection procedure, cancer diagnostics and therapeutics. Anal Biochem. 2020;598:113620. doi: 10.1016/j.ab.2020.113620.
- Lipi F, Chen S, Chakravarthy M, et al. In vitro evolution of chemically-modified nucleic acid aptamers: pros and cons, and comprehensive selection strategies. RNA Biol. 2016;13(12):1232–1245. doi: 10.1080/15476286.2016.1236173.
- Zhuo Z, Yu Y, Wang M, et al. Recent advances in SELEX Technology and aptamer applications in biomedicine. Int J Mol Sci. 2017;18(10):2142. doi: 10.3390/ijms18102142.
- Xiang D, Shigdar S, Bean AG, et al. Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery. Theranostics. 2017;7(17):4071–4086. doi: 10.7150/thno.20168.
- Farrar CT, William CM, Hudry E, et al. RNA aptamer probes as optical imaging agents for the detection of amyloid plaques. PLoS One. 2014;9(2):e89901. doi: 10.1371/journal.pone.0089901.
- Li X, Yang Y, Zhao H, et al. Enhanced in vivo blood-brain barrier penetration by circular tau-transferrin receptor bifunctional aptamer for tauopathy therapy. J Am Chem Soc. 2020;142(8):3862–3872. doi: 10.1021/jacs.9b11490.
- Urak KT, Shore S, Rockey WM, et al. In vitro RNA SELEX for the generation of chemically-optimized therapeutic RNA drugs. Methods. 2016;103:167–174. doi: 10.1016/j.ymeth.2016.03.003.
- Choi JW, Seo M, Kim K, et al. Aptamer nanoconstructs crossing human blood-brain barrier discovered via microphysiological system-based SELEX technology. ACS Nano. 2023;17(9):8153–8166. doi: 10.1021/acsnano.2c11675.
- Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014;9(1):1–25. doi: 10.1146/annurev-pathol-011110-130324.
- Shi S, Fu W, Lin S, et al. Targeted and effective glioblastoma therapy via aptamer-modified tetrahedral framework nucleic acid-paclitaxel nanoconjugates that can pass the blood brain barrier. Nanomedicine. 2019;21:102061. doi: 10.1016/j.nano.2019.102061.
- Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol. 2018;20(suppl_4):iv1–iv86. doi: 10.1093/neuonc/noy131.
- Colombo MC, Giverso C, Faggiano E, et al. Towards the personalized treatment of glioblastoma: integrating patient-specific clinical data in a continuous mechanical model. PLoS One. 2015;10(7):e0132887. doi: 10.1371/journal.pone.0132887.
- Shankar A, Borin TF, Iskander A, et al. Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma. Onco Targets Ther. 2016;9:1205–1219. doi: 10.2147/OTT.S93790.
- Wanjale MV, Kumar GSV. Peptides as a therapeutic avenue for nanocarrier-aided targeting of glioma. Expert Opin Drug Deliv. 2017;14(6):811–824. doi: 10.1080/17425247.2017.1242574.
- Jiang X, Sha X, Xin H, et al. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. Biomaterials. 2011;32(35):9457–9469. doi: 10.1016/j.biomaterials.2011.08.055.
- Hu D, Xia M, Wu L, et al. Challenges and advances for glioma therapy based on inorganic nanoparticles. Mater Today Bio. 2023;20:100673. doi: 10.1016/j.mtbio.2023.100673.
- Wei Z, Zhou Y, Wang R, et al. Aptamers as smart ligands for targeted drug delivery in cancer therapy. Pharmaceutics. 2022;14(12):2561. doi: 10.3390/pharmaceutics14122561.
- Fulton MD, Najahi-Missaoui W. Liposomes in cancer therapy: how did we start and where are we now. Int J Mol Sci. 2023;24(7):6615. doi: 10.3390/ijms24076615.
- Nuzzo S, Brancato V, Affinito A, et al. The role of RNA and DNA aptamers in glioblastoma diagnosis and therapy: a systematic review of the literature. Cancers. 2020;12(8):2173. doi: 10.3390/cancers12082173.
- Mayer G, Menger MM. Nucleic acid aptamers. Vol. 2570. New York (NY): Springer US; 2023.
- Monaco I, Camorani S, Colecchia D, et al. Aptamer functionalization of nanosystems for glioblastoma targeting through the blood-brain barrier. J Med Chem. 2017;60(10):4510–4516. doi: 10.1021/acs.jmedchem.7b00527.
- Yang Y, Yang D, Schluesener HJ, et al. Advances in SELEX and application of aptamers in the central nervous system. Biomol Eng. 2007;24(6):583–592. doi: 10.1016/j.bioeng.2007.06.003.
- Wrona A, Dziadziuszko R, Jassem J. Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents. Transl Lung Cancer Res. 2021;10(4):2032–2047. doi: 10.21037/tlcr-20-552.
- Daniels DA, Chen H, Hicke BJ, et al. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA. 2003;100(26):15416–15421. doi: 10.1073/pnas.2136683100.
- Kong X, Ma W, Li Y, et al. Does tenascin have clinical implications in pathological grade of glioma patients?: A systematic meta-analysis. Medicine. 2015;94(32):e1330. doi: 10.1097/MD.0000000000001330.
- Wan Y, Kim YT, Li N, et al. Surface-immobilized aptamers for cancer cell isolation and microscopic cytology. Cancer Res. 2010;70(22):9371–9380. doi: 10.1158/0008-5472.CAN-10-0568.
- Tan Y, Shi YS, Wu XD, et al. DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro. Acta Pharmacol Sin. 2013;34(12):1491–1498. doi: 10.1038/aps.2013.137.
- Wu X, Liang H, Tan Y, et al. Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo. PLoS One. 2014;9(6):e90752. doi: 10.1371/journal.pone.0090752.
- Giles B, Nakhjavani M, Wiesa A, et al. Unravelling the glioblastoma tumour microenvironment: can aptamer targeted delivery become successful in treating brain cancers? Cancers. 2023;15(17):4376. doi: 10.3390/cancers15174376.
- Hicke BJ, Stephens AW, Gould T, et al. Tumor targeting by an aptamer. J Nucl Med. 2006;47(4):668–678.
- Hasan MR, Hassan N, Khan R, et al. Classification of cancer cells using computational analysis of dynamic morphology. Comput Methods Programs Biomed. 2018;156:105–112. doi: 10.1016/j.cmpb.2017.12.003.
- Mahmood MA, Hasan MR, Khan UJ, et al. One-step tumor detection from dynamic morphology tracking on aptamer-grafted surfaces. Technology. 2015;3(4):194–200. doi: 10.1142/S2339547815500089.
- Camorani S, Crescenzi E, Colecchia D, et al. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells. Oncotarget. 2015;6(35):37570–37587. doi: 10.18632/oncotarget.6066.
- Wan Y, Tan J, Asghar W, et al. Velocity effect on aptamer-based circulating tumor cell isolation in microfluidic devices. J Phys Chem B. 2011;115(47):13891–13896. doi: 10.1021/jp205511m.
- Alibolandi M, Abnous K, Ramezani M, et al. Synthesis of AS1411-aptamer-conjugated CdTe quantum dots with high fluorescence strength for probe labeling tumor cells. J Fluoresc. 2014;24(5):1519–1529. doi: 10.1007/s10895-014-1437-5.
- Bayrac AT, Sefah K, Parekh P, et al. In vitro selection of DNA aptamers to glioblastoma multiforme. ACS Chem Neurosci. 2011;2(3):175–181. doi: 10.1021/cn100114k.
- Obrador E, Moreno-Murciano P, Oriol-Caballo M, et al. Glioblastoma therapy: past, present and future. Int J Mol Sci. 2024;25(5):2529. doi: 10.3390/ijms25052529.
- Kim Y, Wu Q, Hamerlik P, et al. Aptamer identification of brain tumor-initiating cells. Cancer Res. 2013;73(15):4923–4936. 1doi: 10.1158/0008-5472.CAN-12-4556.
- Kang D, Wang J, Zhang W, et al. Selection of DNA aptamers against glioblastoma cells with high affinity and specificity. PLoS One. 2012;7(10):e42731. doi: 10.1371/journal.pone.0042731.
- Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11(4):689–708. doi: 10.1677/erc.1.00600.
- Shibabaw T, Teferi B, Ayelign B. The role of Th-17 cells and IL-17 in the metastatic spread of breast cancer: as a means of prognosis and therapeutic target. Front Immunol. 2023;14:1094823. doi: 10.3389/fimmu.2023.1094823.
- Wang T, Philippovich S, Mao J, et al. Efficient epidermal growth factor receptor targeting oligonucleotide as a potential molecule for targeted cancer therapy. Int J Mol Sci. 2019;20(19):4700. 22doi: 10.3390/ijms20194700.
- Li N, Nguyen HH, Byrom M, et al. Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One. 2011;6(6):e20299. doi: 10.1371/journal.pone.0020299.
- Zhang X, Peng L, Liang Z, et al. Effects of aptamer to U87-EGFRvIII cells on the proliferation, radiosensitivity, and radiotherapy of glioblastoma cells. Mol Ther Nucleic Acids. 2018;10:438–449. doi: 10.1016/j.omtn.2018.01.001.
- Camorani S, Esposito CL, Rienzo A, et al. Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer. Mol Ther. 2014;22(4):828–841. doi: 10.1038/mt.2013.300.
- Pudełek M, Król K, Catapano J, et al. Epidermal growth factor (EGF) augments the invasive potential of human glioblastoma multiforme cells via the activation of collaborative EGFR/ROS-dependent signaling. Int J Mol Sci. 2020;21(10):3605. doi: 10.3390/ijms21103605.
- Thomas BJ, Guldenpfennig C, Guan Y, et al. Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer. Mol Ther Nucleic Acids. 2023;34:102046. doi: 10.1016/j.omtn.2023.102046.
- Liu Y, Kuan CT, Mi J, et al. Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol Chem. 2009;390(2):137–144. doi: 10.1515/BC.2009.022.
- Peng L, Liang Y, Zhong X, et al. Aptamer-conjugated gold nanoparticles targeting epidermal growth factor receptor variant III for the treatment of glioblastoma. Int J Nanomedicine. 2020;15(1):1363–1372. doi: 10.2147/IJN.S238206.
- Zhang X, Liang H, Tan Y, et al. A U87-EGFRvIII cell-specific aptamer mediates small interfering RNA delivery. Biomed Rep. 2014;2(4):495–499. doi: 10.3892/br.2014.276.
- Affinito A, Quintavalle C, Esposito CL, et al. Targeting ephrin receptor tyrosine kinase A2 with a selective aptamer for glioblastoma stem cells. Mol Ther Nucleic Acids. 2020;20(1):176–185. doi: 10.1016/j.omtn.2020.02.005.
- Amero P, Esposito CL, Rienzo A, et al. Identification of an interfering ligand aptamer for EphB2/3 receptors. 2016;26(2):102–110. https://www.liebertpub.com/doi/10.1089/nat.2015.0580.
- Fu W, You C, Ma L, et al. Enhanced efficacy of temozolomide loaded by a tetrahedral framework DNA nanoparticle in the therapy for glioblastoma. ACS Appl Mater Interfaces. 2019;11(43):39525–39533. https://pubs.acs.org/doi/abs/10.1021/acsami.9b13829 doi: 10.1021/acsami.9b13829.
- Luo Z, Yan Z, Jin K, et al. Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-γ-glutamylglutamine)–paclitaxel nanoconjugates. J Colloid Interface Sci. 2017;490:783–796. doi: 10.1016/j.jcis.2016.12.004.
- Verhoeff JJC, Stalpers LJA, Claes A, et al. Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. Eur J Cancer. 2009;45(17):3074–3080. http://www.ejcancer.com/article/S0959804909005863/fulltext doi: 10.1016/j.ejca.2009.08.004.
- Yoon S, Wu X, Armstrong B, et al. An RNA aptamer targeting the receptor tyrosine kinase PDGFRα induces anti-tumor effects through STAT3 and p53 in glioblastoma. Mol Ther Nucleic Acids. 2019;14:131–141. https://pubmed.ncbi.nlm.nih.gov/30594071/ doi: 10.1016/j.omtn.2018.11.012.
- Esposito CL, Nuzzo S, Kumar SA, et al. A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells. J Control Release. 2016;238:43–57. https://pubmed.ncbi.nlm.nih.gov/27448441/ doi: 10.1016/j.jconrel.2016.07.032.
- Wei J, Marisetty A, Schrand B, et al. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019;129(1):137–149. https://pubmed.ncbi.nlm.nih.gov/30307407/ doi: 10.1172/JCI121266.
- Affinito A, Quintavalle C, Esposito CL, et al. The discovery of RNA aptamers that selectively bind glioblastoma stem cells. Mol Ther Nucleic Acids. 2019;18:99–109. doi: 10.1016/j.omtn.2019.08.015.
- Ong DST, Hu B, Ho YW, et al. PAF promotes stemness and radioresistance of glioma stem cells. Proc Natl Acad Sci USA. 2017;114(43):E9085–E9095. https://www.pnas.org/doi/abs/10.1073/pnas.1708122114 doi: 10.1073/pnas.1708122114.
- Zhang Q, Xiang W, Yi D-Y, et al. Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas. Stem Cell Res Ther. 2018;9(1):228. https://pubmed.ncbi.nlm.nih.gov/30143053/ doi: 10.1186/s13287-018-0977-z.
- Day BW, Stringer BW, Boyd AW. Eph receptors as therapeutic targets in glioblastoma. Br J Cancer. 2014;111(7):1255–1261. https://www.nature.com/articles/bjc201473 doi: 10.1038/bjc.2014.73.
- Wykosky J, Gibo DM, Stanton C, et al. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res. 2005;3(10):541–551. doi: 10.1158/1541-7786.MCR-05-0056.
- Wu N, Zhao X, Liu M, et al. Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS One. 2011;6(1):e16264. https://pubmed.ncbi.nlm.nih.gov/21264258/ doi: 10.1371/journal.pone.0016264.
- Li X, Wang Y, Wang Y, et al. Expression of EphA2 in human astrocytic tumors: correlation with pathologic grade, proliferation and apoptosis. Tumour Biol. 2007;28(3):165–172. https://pubmed.ncbi.nlm.nih.gov/17519535/ doi: 10.1159/000103010.
- Wang LF, Fokas E, Bieker M, et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep. 2008;19(1):151–156. doi: 10.3892/or.19.1.151.
- Gai Q-J, Fu Z, He J, et al. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma. Signal Transduct Target Ther. 2022;7(1):33. doi: 10.1038/s41392-021-00855-2.
- Zhang Y, Hong H, Cai W. Tumor-targeted drug delivery with aptamers. Curr Med Chem. 2011;18(27):4185–4194. doi: 10.2174/092986711797189547.
- Iaboni M, Russo V, Fontanella R, et al. Aptamer-miRNA-212 conjugate sensitizes NSCLC cells to TRAIL. Mol Ther Nucleic Acids. 2016;5(3):e289. doi: 10.1038/mtna.2016.5.
- Esposito CL, Catuogno S, Condorelli G, et al. Aptamer chimeras for therapeutic delivery: the challenging perspectives. Genes. 2018;9(11):529. doi: 10.3390/genes9110529.
- Catuogno S, Esposito CL, Condorelli G, et al. Nucleic acids delivering nucleic acids. Adv Drug Deliv Rev. 2018;134:79–93. doi: 10.1016/j.addr.2018.04.006.
- Russo V, Paciocco A, Affinito A, et al. Aptamer-miR-34c conjugate affects cell proliferation of non-small-cell lung cancer cells. Mol Ther Nucleic Acids. 2018;13:334–346. doi: 10.1016/j.omtn.2018.09.016.
- Esposito CL, Cerchia L, Catuogno S, et al. Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Mol Ther. 2014;22(6):1151–1163. doi: 10.1038/mt.2014.5.
- Sasmita AO, Wong YP, Ling APK. Biomarkers and therapeutic advances in glioblastoma multiforme. Asia Pac J Clin Oncol. 2018;14(1):40–51. https://onlinelibrary.wiley.com/doi/full/10.1111/ajco.12756 doi: 10.1111/ajco.12756.
- Lang M-F, Yang S, Zhao C, et al. Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One. 2012;7(4):e36248. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0036248 doi: 10.1371/journal.pone.0036248.
- Chen L, Kang C, Chen L, et al. miRNA interventions serve as ‘magic bullets’ in the reversal of glioblastoma hallmarks. Oncotarget. 2015;6(36):38628–38642. https://www.oncotarget.com/article/5926/text/ doi: 10.18632/oncotarget.5926.
- Lulli V, Buccarelli M, Martini M, et al. miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. Oncotarget. 2015;6(35):37241–37256. doi: 10.18632/oncotarget.5925.
- Teplyuk NM, Uhlmann EJ, Gabriely G, et al. Therapeutic potential of targeting micro RNA-10b in established intracranial glioblastoma: first steps toward the clinic. EMBO Mol Med. 2016;8(3):268–287. doi: 10.15252/emmm.201505495.
- Liang M-L, Hsieh T-H, Ng K-H, et al. Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas molecular and genetic imaging core/Taiwan mouse clinic national comprehensive mouse phenotyping and drug testing. Oncotarget. 2016;7(15):19723–19737. doi: 10.18632/oncotarget.7736.
- Kanlikilicer P, Ozpolat B, Aslan B, et al. Therapeutic targeting of AXL receptor tyrosine kinase inhibits tumor growth and intraperitoneal metastasis in ovarian cancer models. Mol Ther Nucleic Acids. 2017;9:251–262. doi: 10.1016/j.omtn.2017.06.023.
- Akhavan D, Pourzia AL, Nourian AA, et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013;3(5):534–547. doi: 10.1158/2159-8290.CD-12-0502.
- Wu X, Ma W, Zhou Q, et al. AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases. J Cancer Res Clin Oncol. 2017;143(10):1947–1957. https://pubmed.ncbi.nlm.nih.gov/28551766/ doi: 10.1007/s00432-017-2408-4.
- Catuogno S, Rienzo A, Di Vito A, et al. Selective delivery of therapeutic single strand antimiRs by aptamer-based conjugates. J Control Release. 2015;210:147–159. doi: 10.1016/j.jconrel.2015.05.276.
- Bier A, Giladi N, Kronfeld N, et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 2013;4(5):665–676. https://www.oncotarget.com/article/928/text/ doi: 10.18632/oncotarget.928.
- Gao H, Qian J, Yang Z, et al. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(ε-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials. 2012;33(26):6264–6272. doi: 10.1016/j.biomaterials.2012.05.020.
- Rad AH, Asiaee F, Jafari S, et al. Poly(ethylene glycol)-poly(ε-caprolactone)-based micelles for solubilization and tumor-targeted delivery of silibinin. Bioimpacts. 2020;10(2):87–95. https://pmc/articles/PMC7186544/ doi: 10.34172/bi.2020.11.
- Sampath P, Rhines LD, DiMeco F, et al. Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma. J Neurooncol. 2006;80(1):9–17. https://pubmed.ncbi.nlm.nih.gov/16636748/ doi: 10.1007/s11060-006-9159-4.
- Guéritte-Voegelein F, Guénard D, Le Goff MT, et al. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem. 1991;34(3):992–998. https://pubmed.ncbi.nlm.nih.gov/1672159/ doi: 10.1021/jm00107a017.
- Huile G, Shuaiqi P, Zhi Y, et al. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomaterials. 2011;32(33):8669–8675. doi: 10.1016/j.biomaterials.2011.07.069.
- Gao HL, Pang ZQ, Fan L, et al. Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: in vitro and in vivo evaluations. Acta Pharmacol Sin. 2010;31(2):237–243. https://pubmed.ncbi.nlm.nih.gov/20139907/ doi: 10.1038/aps.2009.199.
- Rosenberg JE, Bambury RM, Van Allen EM, et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs. 2014;32(1):178–187. https://pubmed.ncbi.nlm.nih.gov/24242861/ doi: 10.1007/s10637-013-0045-6.
- Hu X, Zhang D, Zeng Z, et al. Aptamer-based probes for cancer diagnostics and treatment. Life. 2022;12(11):1937. https://pubmed.ncbi.nlm.nih.gov/36431072/ doi: 10.3390/life12111937.
- Bates PJ, Laber DA, Miller DM, et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009;86(3):151–164. https://pubmed.ncbi.nlm.nih.gov/19454272/ doi: 10.1016/j.yexmp.2009.01.004.
- Bates PJ, Kahlon JB, Thomas SD, et al. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem. 1999;274(37):26369–26377. https://pubmed.ncbi.nlm.nih.gov/10473594/ doi: 10.1074/jbc.274.37.26369.
- Jia W, Yao Z, Zhao J, et al. New perspectives of physiological and pathological functions of nucleolin (NCL). Life Sci. 2017;186:1–10. https://pubmed.ncbi.nlm.nih.gov/28751161/ doi: 10.1016/j.lfs.2017.07.025.
- Galzio R, Rosati F, Benedetti E, et al. Glycosilatednucleolin as marker for human gliomas. J Cell Biochem. 2012;113(2):571–579. https://pubmed.ncbi.nlm.nih.gov/21938743/ doi: 10.1002/jcb.23381.
- Goldshmit Y, Trangle SS, Kloog Y, et al. Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma. Oncotarget. 2014;5(18):8602–8613. doi: 10.18632/oncotarget.2343.
- Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal. 2009;2(87):re6. https://pubmed.ncbi.nlm.nih.gov/19738203/ doi: 10.1126/scisignal.287re6.
- Abdelmohsen K, Gorospe M. RNA-binding protein nucleolin in disease. RNA Biol. 2012;9(6):799–808. https://pubmed.ncbi.nlm.nih.gov/22617883/ doi: 10.4161/rna.19718.
- Xu X, Hamhouyia F, Thomas SD, et al. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem. 2001;276(46):43221–43230. https://pubmed.ncbi.nlm.nih.gov/11555643/ doi: 10.1074/jbc.M104446200.
- Thongchot S, Aksonnam K, Thuwajit P, et al. Nucleolin-based targeting strategies in cancer treatment: focus on cancer immunotherapy (Review). Int J Mol Med. 2023;52(3):81. https://pubmed.ncbi.nlm.nih.gov/37477132/ doi: 10.3892/ijmm.2023.5284.
- Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl. 2006;45(8):1198–1215. https://pubmed.ncbi.nlm.nih.gov/16444775/ doi: 10.1002/anie.200502113.
- Sabbatini P, Aghajanian C, Dizon D, et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol. 2004;22(22):4523–4531. doi: 10.1200/JCO.2004.12.043.
- Veronese ML, Flaherty K, Kramer A, et al. Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005;55(5):497–501. https://europepmc.org/article/MED/15711828 doi: 10.1007/s00280-004-0938-3.
- Guo J, Gao X, Su L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011;32(31):8010–8020. https://pubmed.ncbi.nlm.nih.gov/21788069/ doi: 10.1016/j.biomaterials.2011.07.004.
- Ranganath SH, Fu Y, Arifin DY, et al. The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials. 2010;31(19):5199–5207. https://pubmed.ncbi.nlm.nih.gov/20350766/ doi: 10.1016/j.biomaterials.2010.03.002.
- Zhang B, Zhang Y, Liao Z, et al. UPA-sensitive ACPP-conjugated nanoparticles for multi-targeting therapy of brain glioma. Biomaterials. 2015;36:98–109. doi: 10.1016/j.biomaterials.2014.09.008.
- Zhang B, Sun X, Mei H, et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials. 2013;34(36):9171–9182. https://pubmed.ncbi.nlm.nih.gov/24008043/ doi: 10.1016/j.biomaterials.2013.08.039.
- André N, Carré M, Brasseur G, et al. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett. 2002;532(1-2):256–260. doi: 10.1016/s0014-5793(02)03691-8.
- Wang TH, Wang HS, Soong YK, et al. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000;88(11):2619–2628. doi: 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J.
- Chen Y, Feng S, Liu W, et al. Vitamin E succinate-grafted-chitosan oligosaccharide/RGD-conjugated TPGS mixed micelles loaded with paclitaxel for U87MG tumor therapy. Mol Pharm. 2017;14(4):1190–1203. https://pubmed.ncbi.nlm.nih.gov/28212490/ doi: 10.1021/acs.molpharmaceut.6b01068.
- Van S, Das SK, Wang X, et al. Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate. Int J Nanomedicine. 2010;5(1):825–837. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21042550/?tool=EBI doi: 10.2147/IJN.S13482.
- Yang D, Yu L, Van S. Clinically relevant anticancer polymer paclitaxel therapeutics. Cancers. 2010;3(1):17–42. https://pubmed.ncbi.nlm.nih.gov/24212604/ doi: 10.3390/cancers3010017.
- Li X, Xie X, Ma Z, et al. Programming niche accessibility and in vitro stemness with intercellular DNA reactions. Adv Mater. 2018;30(46):e1804861–e1804861. https://europepmc.org/article/MED/30276898 doi: 10.1002/adma.201804861.
- Chen F, Bai M, Cao K, et al. Programming enzyme-initiated autonomous DNAzyme nanodevices in living cells. ACS Nano. 2017;11(12):11908–11914. https://pubs.acs.org/doi/abs/10.1021/acsnano.7b06728 doi: 10.1021/acsnano.7b06728.
- Zhu D, Pei H, Yao G, et al. A surface-confined proton-driven DNA pump using a dynamic 3D DNA scaffold. Adv Mater. 2016;28(32):6860–6865. https://europepmc.org/article/MED/27218679 doi: 10.1002/adma.201506407.
- Zhang Q, Lin S, Shi S, et al. Anti-inflammatory and antioxidative effects of tetrahedral DNA nanostructures via the modulation of macrophage responses. ACS Appl Mater Interfaces. 2018;10(4):3421–3430. doi: 10.1021/acsami.7b17928.
- Shao X, Ma W, Xie X, et al. Neuroprotective effect of tetrahedral DNA nanostructures in a cell model of Alzheimer’s disease. ACS Appl Mater Interfaces. 2018;10(28):23682–23692. https://pubs.acs.org/doi/pdf/10.1021/acsami.8b07827 doi: 10.1021/acsami.8b07827.
- Zhang Y, Ma W, Zhu Y, et al. Inhibiting methicillin-resistant Staphylococcus aureus by tetrahedral DNA nanostructure-enabled antisense peptide nucleic acid delivery. Nano Lett. 2018;18(9):5652–5659. https://europepmc.org/article/MED/30088771 doi: 10.1021/acs.nanolett.8b02166.
- Xie X, Shao X, Ma W, et al. Overcoming drug-resistant lung cancer by paclitaxel loaded tetrahedral DNA nanostructures. Nanoscale. 2018;10(12):5457–5465. https://pubmed.ncbi.nlm.nih.gov/29484330/ doi: 10.1039/c7nr09692e.
- Roos WP, Batista LFZ, Naumann SC, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007;26(2):186–197. https://pubmed.ncbi.nlm.nih.gov/16819506/ doi: 10.1038/sj.onc.1209785.
- Günther W, Pawlak E, Damasceno R, et al. Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br J Cancer. 2003;88(3):463–469. https://pubmed.ncbi.nlm.nih.gov/12569392/ doi: 10.1038/sj.bjc.6600711.
- Knizhnik AV, Roos WP, Nikolova T, et al. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS One. 2013;8(1):e55665. https://mdanderson.elsevierpure.com/en/publications/survival-and-death-strategies-in-glioma-cells-autophagy-senescenc doi: 10.1371/journal.pone.0055665.
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. https://pubmed.ncbi.nlm.nih.gov/15758009/ doi: 10.1056/NEJMoa043330.
- Hersh DS, Harder BG, Roos A, et al. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance. Neuro Oncol. 2018;20(10):1321–1330. https://mayoclinic.elsevierpure.com/en/publications/the-tnf-receptor-family-member-fn14-is-highly-expressed-in-recurr doi: 10.1093/neuonc/noy063.
- Chen X, Zhang M, Gan H, et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun. 2018;9(1):2949. https://pubmed.ncbi.nlm.nih.gov/30054476/ doi: 10.1038/s41467-018-05373-4.
- Le Rhun E, von Achenbach C, Lohmann B, et al. Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition. Int J Cancer. 2019;145(1):242–253. https://pubmed.ncbi.nlm.nih.gov/30549269/ doi: 10.1002/ijc.32069.
- Nie E, Miao F, Jin X, et al. Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma. Oncogene. 2019;38(15):2706–2721. https://pmc/articles/PMC6484760/ doi: 10.1038/s41388-018-0596-2.
- Wick W, Dettmer S, Berberich A, et al. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro Oncol. 2019;21(1):95–105. https://pubmed.ncbi.nlm.nih.gov/30277538/ doi: 10.1093/neuonc/noy161.
- Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol. 2019;21(2):167–178. https://pubmed.ncbi.nlm.nih.gov/30189035/ doi: 10.1093/neuonc/noy132.
- Kessler T, Sahm F, Sadik A, et al. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Neuro Oncol. 2018;20(3):367–379. doi: 10.1093/neuonc/nox160.
- Jutten B, Keulers TG, Peeters HJM, et al. EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability sensitive to autophagy inhibition. Autophagy. 2018;14(2):283–295. https://pubmed.ncbi.nlm.nih.gov/29377763/ doi: 10.1080/15548627.2017.1409926.
- Lammering G, Hewit TH, Holmes M, et al. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res. 2004;10(19):6732–6743. https://pubmed.ncbi.nlm.nih.gov/15475464/ doi: 10.1158/1078-0432.CCR-04-0393.
- Her S, Jaffray DA, Allen C. Gold nanoparticles for applications in cancer radiotherapy: mechanisms and recent advancements. Adv Drug Deliv Rev. 2017;109:84–101. https://pubmed.ncbi.nlm.nih.gov/26712711/ doi: 10.1016/j.addr.2015.12.012.
- Liu J, Peng Q. Protein-gold nanoparticle interactions and their possible impact on biomedical applications. Acta Biomater. 2017;55:13–27. https://pubmed.ncbi.nlm.nih.gov/28377307/ doi: 10.1016/j.actbio.2017.03.055.
- Kouri FM, Hurley LA, Daniel WL, et al. miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes Dev. 2015;29(7):732–745. https://pubmed.ncbi.nlm.nih.gov/25838542/ doi: 10.1101/gad.257394.114.
- Mirza-Aghazadeh-Attari M, Mohammadzadeh A, Yousefi B, et al. 53BP1: a key player of DNA damage response with critical functions in cancer. DNA Repair. 2019;73:110–119. https://pubmed.ncbi.nlm.nih.gov/30497961/ doi: 10.1016/j.dnarep.2018.11.008.
- Dineen RA, Whitehouse WP. Ataxia telangiectasia. In: Essentials of cerebellum and cerebellar disorders: a primer for graduate students. 2nd ed. Treasure Island (FL): StatPearls Publishing; 2023. p. 621–630. https://www.ncbi.nlm.nih.gov/books/NBK519542/
- Zannini L, Delia D, Buscemi G. CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol. 2014;6(6):442–457. doi: 10.1093/jmcb/mju045.
- Srivatsa S, Paul MC, Cardone C, et al. EGFR in tumor-associated myeloid cells promotes development of colorectal cancer in mice and associates with outcomes of patients. Gastroenterology. 2017;153(1):178–190.e10. doi: 10.1053/j.gastro.2017.03.053.
- Tan W, Wang H, Chen Y, et al. Molecular aptamers for drug delivery. Trends Biotechnol. 2011;29(12):634–640. http://www.cel0l.com/article/S0167779911001132/fulltext doi: 10.1016/j.tibtech.2011.06.009.
- Akbulut H. Immune gene therapy of cancer. Turk J Med Sci. 2020;50(SI-2):1679–1690. https://pubmed.ncbi.nlm.nih.gov/32512674/ doi: 10.3906/sag-2005-327.
- Wang C, Lin GHY, McPherson AJ, et al. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev. 2009;229(1):192–215. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1600-065X.2009.00765.x doi: 10.1111/j.1600-065X.2009.00765.x.
- Singh R, Kim YH, Lee SJ, et al. 4-1BB immunotherapy: advances and hurdles. Exp Mol Med. 2024;56(1):32–39. https://pubmed.ncbi.nlm.nih.gov/38172595/ doi: 10.1038/s12276-023-01136-4.
- Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089–1096. doi: 10.1158/0008-5472.1089.65.3.
- Kocak E, Lute K, Chang X, et al. Combination therapy with anti–CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 2006;66(14):7276–7284. doi: 10.1158/0008-5472.CAN-05-2128.
- Xu DP, Sauter BV, Huang TG, et al. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther. 2005;12(20):1526–1533. https://www.nature.com/articles/3302556 doi: 10.1038/sj.gt.3302556.
- Schrand B, Berezhnoy A, Brenneman R, et al. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res. 2014;2(9):867–877. doi: 10.1158/2326-6066.CIR-14-0007.
- John LB, Howland LJ, Flynn JK, et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res. 2012;72(7):1651–1660. doi: 10.1158/0008-5472.CAN-11-2788.
- Doucette TA, Kong L-Y, Yang Y, et al. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012;14(9):1136–1145. doi: 10.1093/neuonc/nos139.
- Hashimoto K, Modjtahedi H. CD137 as an attractive T cell co-stimulatory target in the TNFRSF for immuno-oncology drug development. Cancers. 2021;13(10):2288. https://www.mdpi.com/2072-6694/13/10/2288/htm doi: 10.3390/cancers13102288.
- Houot R, Goldstein MJ, Kohrt HE, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood. 2009;114(16):3431–3438. doi: 10.1182/blood-2009-05-223958.
- Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res. 2004;121(2):228–241. http://www.journalofsurgicalresearch.com/article/S0022480404001362/fulltext doi: 10.1016/j.jss.2004.03.028.
- Qin YC, Yan X, Yu WW, et al. Osteopontin promotes gastric cancer progression via phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway. World J Gastrointest Oncol. 2023;15(9):1544–1555. https://pubmed.ncbi.nlm.nih.gov/37746644/ doi: 10.4251/wjgo.v15.i9.1544.
- Kim E-K, Jeon I, Seo H, et al. Tumor-derived osteopontin suppresses antitumor immunity by promoting extramedullary myelopoiesis. Cancer Res. 2014;74(22):6705–6716. doi: 10.1158/0008-5472.CAN-14-1482.
- Cantor H, Shinohara ML. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat Rev Immunol. 2009;9(2):137–141. https://www.nature.com/articles/nri2460 doi: 10.1038/nri2460.
- Renkl AC, Wussler J, Ahrens T, et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood. 2005;106(3):946–955. doi: 10.1182/blood-2004-08-3228.
- Cui G, Chen J, He J, et al. Osteopontin promotes dendritic cell maturation and function in response to HBV antigens. Drug Des Devel Ther. 2015;9:3003–3016. https://pubmed.ncbi.nlm.nih.gov/26109844/ doi: 10.2147/DDDT.S81656.
- Henry A, Nokin M-J, Leroi N, et al. New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity. Oncotarget. 2016;7(39):63708–63721. https://pubmed.ncbi.nlm.nih.gov/27563812/ doi: 10.18632/oncotarget.11483.
- Jain KK. A critical overview of targeted therapies for glioblastoma. Front Oncol. 2018;8(1):419. doi: 10.3389/fonc.2018.00419.
- Nuzzo S, Roscigno G, Affinito A, et al. Potential and challenges of aptamers as specific carriers of therapeutic oligonucleotides for precision medicine in cancer. Cancers. 2019;11(10):1521. https://www.mdpi.com/2072-6694/11/10/1521/htm doi: 10.3390/cancers11101521.
- Olusanya TOB, Ahmad RRH, Ibegbu DM, et al. Liposomal drug delivery systems and anticancer drugs. Molecule. 2018;23(4):907. https://www.mdpi.com/1420-3049/23/4/907/htm doi: 10.3390/molecules23040907.
- V Y A, S M M, Sa S, et al. Stability aspects of liposomes. Indian J Pharm Res Educ. 2011;45(4):402–413.
- Briuglia ML, Rotella C, McFarlane A, et al. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv Transl Res. 2015;5(3):231–242. doi: 10.1007/s13346-015-0220-8.
- Manzoor AA, Lindner LH, Landon CD, et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 2012;72(21):5566–5575. doi: 10.1158/0008-5472.CAN-12-1683.
- Baker JHE, Lindquist KE, Huxham LA, et al. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res. 2008;14(7):2171–2179. doi: 10.1158/1078-0432.CCR-07-4465.
- Patel MA, Pardoll DM. Concepts of immunotherapy for glioma. J Neurooncol. 2015;123(3):323–330. doi: 10.1007/s11060-015-1810-5.
- Katz MG, Fargnoli AS, Williams RD, et al. Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications. Hum Gene Ther. 2013;24(11):914–927. https://www.liebertpub.com/doi/10.1089/hum.2013.2517
- Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2016;16(3):181–202. https://www.nature.com/articles/nrd.2016.199 doi: 10.1038/nrd.2016.199.
- Gupta S, Drolet DW, Wolk SK, et al. Pharmacokinetic properties of DNA aptamers with base modifications. Nucleic Acid Ther. 2017;27(6):345–353. https://www.liebertpub.com/doi/10.1089/nat.2017.0683 doi: 10.1089/nat.2017.0683.
- Lincoff AM, Mehran R, Povsic TJ, et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet. 2016;387(10016):349–356. http://www.thelancet.com/article/S0140673615005152/fulltext
- Ganson NJ, Povsic TJ, Sullenger BA, et al. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol. 2016;137(5):1610–1613.e7. http://www.jacionline.org/article/S009167491501667X/fulltext doi: 10.1016/j.jaci.2015.10.034.
- Borbas KE, Ferreira CSM, Perkins A, et al. Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. Bioconjug Chem. 2007;18(4):1205–1212. https://pubs.acs.org/doi/abs/10.1021/bc0700741 doi: 10.1021/bc0700741.
- Lächelt U, Wagner E. Nucleic acid therapeutics using polyplexes: a journey of 50 years (and beyond). Chem Rev. 2015;115(19):11043–11078. https://pubs.acs.org/doi/abs/10.1021/cr5006793 doi: 10.1021/cr5006793.
- Wu H, Lima WF, Zhang H, et al. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem. 2004;279(17):17181–17189. https://pubmed.ncbi.nlm.nih.gov/14960586/ doi: 10.1074/jbc.M311683200.
- Shen X, Corey DR. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 2018;46(4):1584–1600. doi: 10.1093/nar/gkx1239.
- Esawi E, Nsairat H, Mahmoud IS, et al. Clinical use and future perspective of aptamers. In: Aptamers engineered nanocarriers for cancer therapy. Cambridge: Woodhead Publishing; 2023. p. 481–520.
- Huang Z, Wang D, Zhang Q, et al. Leveraging aptamer-based DNA nanotechnology for bioanalysis and cancer therapeutics. Acc Mater Res. 2023;5(4):438–452. doi: 10.1021/accountsmr.3c00249.
- Giles B, Samarasinghe R, Shigdar S. Rising to the challenge: recent aptamer-conjugate success in treating glioblastoma. https://www.researchgate.net/publication/369416681.